Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 7/2016

01-07-2016 | Osteoarthritis (MB Goldring, Section Editor)

The Role of Sirtuins in Cartilage Homeostasis and Osteoarthritis

Authors: Mona Dvir-Ginzberg, Ali Mobasheri, Ashok Kumar

Published in: Current Rheumatology Reports | Issue 7/2016

Login to get access

Abstract

The past decade has witnessed many advances in the understanding of sirtuin biology and related regulatory circuits supporting the capacity of these proteins to serve as energy-sensing molecules that contribute to healthspan in various tissues, including articular cartilage. Hence, there has been a significant increase in new investigations that aim to elucidate the mechanisms of sirtuin function and their roles in cartilage biology, skeletal development, and pathologies such as osteoarthritis (OA), rheumatoid arthritis (RA), and intervertebral disc degeneration (IVD). The majority of the work carried out to date has focused on SIRT1, although SIRT6 has more recently become a focus of some investigations. In vivo work with transgenic mice has shown that Sirt1 and Sirt6 are essential for maintaining cartilage homeostasis and that the use of sirtuin-activating molecules such as resveratrol may have beneficial effects on cartilage anabolism. Current thinking is that SIRT1 exerts positive effects on cartilage by encouraging chondrocyte survival, especially under stress conditions, which may provide a mechanism supporting the use of sirtuin small-molecule activators (STACS) for future therapeutic interventions in OA and other degenerative pathologies of joints, especially those that involve articular cartilage.
Literature
1.
Mobasheri A, Matta C, Zákány R, Musumeci G. Chondrosenescence: definition, hallmarks and potential role in the pathogenesis of osteoarthritis. Maturitas. 2015;80(3):237–44.CrossRefPubMed
2.
Iannone F, Lapadula G. The pathophysiology of osteoarthritis. Aging Clin Exp Res. 2003;15(5):364–72.CrossRefPubMed
3.
Hunter DJ, Schofield D, Callander E. The individual and socioeconomic impact of osteoarthritis. Nat Rev Rheumatol. 2014;10(7):437–41.PubMed
4.
Malfait AM. Osteoarthritis year in review 2015: biology. Osteoarthritis Cartilage. 2016;24(1):21–6.CrossRefPubMed
5.
Bay-Jensen AC, Reker D, Kjelgaard-Petersen CF, Mobasheri A, Karsdal MA, Ladel C, et al. Osteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria. Osteoarthritis Cartilage. 2016;24(1):9–20.CrossRefPubMed
6.
Peytremann-Bridevaux I, Faeh D, Santos-Eggimann B. Prevalence of overweight and obesity in rural and urban settings of 10 European countries. Prev Med. 2007;44(5):442–6.CrossRefPubMed
7.
Dvir-Ginzberg M, Gagarina V, Lee EJ, Hall DJ. Regulation of cartilage-specific gene expression in human chondrocytes by SirT1 and nicotinamide phosphoribosyltransferase. J Biol Chem. 2008;52:36300–10.CrossRef
8.
9.
Sinclair DA, Guarente L. Extra chromosomal rDNA circles—a cause of aging in yeast. Cell. 1997;91(7):1033–42.CrossRefPubMed
10.
Bordone L, Cohen D, Robinson A, Motta MC, van Veen E, Czopik A, et al. Guarente L.SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell. 2007;6(6):759–67.CrossRefPubMed
11.
Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007;450(7170):712–6.CrossRefPubMedPubMedCentral
12.
Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127(6):1109–22.CrossRefPubMed
13.
McBurney MW, Clark-Knowles KV, Caron AZ, Gray DA. SIRT1 is a highly networked protein that mediates the adaptation to chronic physiological stress. Genes Cancer. 2013;4(3-4):125–34.CrossRefPubMedPubMedCentral
14.
Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y. Nucleocytoplasmic shuttling of the NAD + -dependent histone deacetylase SIRT1. J Biol Chem. 2007;282(9):6823–32.CrossRefPubMed
15.
Austin S, St-Pierre J. PGC1α and mitochondrial metabolism-emerging concepts and relevance in ageing and neurodegenerative disorders, J. Cell Sci. 2012;125(Pt 21):4963–71.
16.
Morris BJ. Seven sirtuins for seven deadly diseases of aging, Free Radic. Biol. Med. 2013;56:133–71.
17.
Southwood CM, Peppi M, Dryden S, Tainsky Ma, Gow A. Microtubule deacetylases, SirT2 and HDAC6, in the nervous system, Neurochem. Res. 2007;32:187–95.
18.
Anderson KA, Green MF, Huynh FK, Wagner GR, Hirschey MD. SnapShot : mammalian sirtuins, Cell. 2014;159:956–956.
19.
Brachmann CB, Sherman JM, Devine SE, Cameron EE, Pillus L, Boeke JD. The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability, Genes Dev. 1995;9:2888–902.
20.
North BJ, Marshall BL, Borra MT, Denu JM, Verdin E, Francisco S. The human Sir2 ortholog, SIRT2, is an NAD-dependent tubulin deacetylase, Mol. Cell. 2003;11:437–44.
21.
Scher MB, Vaquero A, Reinberg D. SirT3 is a nuclear NAD+-dependent histone deacetylase that translocates to the mitochondria upon cellular stress, Genes Dev. 2007;21:920–8.
22.
Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ, et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell. 2006;126(5):941–54.CrossRefPubMed
23.
Nakagawa T, Lomb DJ, Haigis MC, Guarente L. SIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell. 2009;137(3):560–70.CrossRefPubMedPubMedCentral
24.
Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012;483(7388):218–21.CrossRefPubMed
25.
Grob A, Roussel P, Wright JE, McStay B, Hernandez-Verdun D, Sirri V. Involvement of SIRT7 in resumption of rDNA transcription at the exit from mitosis. J Cell Sci. 2009;122(Pt 4):489–98.CrossRefPubMedPubMedCentral
26.••
Gabay O, Oppenhiemer H, Meir H, Zaal K, Sanchez C, Dvir-Ginzberg M. Increased apoptotic chondrocytes in articular cartilage from adult heterozygous SirT1 mice. Ann Rheum Dis. 2012;71(4):613–6. First study to show SIRT1 relevance to OA in-vivo transgenic mice.CrossRefPubMedPubMedCentral
27.
Gabay O, Zaal KJ, Sanchez C, Dvir-Ginzberg M, Gagarina V, Song Y, et al. Sirt1-deficient mice exhibit an altered cartilage phenotype. Joint Bone Spine. 2013;80(6):613–20.CrossRefPubMedPubMedCentral
28.
Gabay O, Sanchez C, Dvir-Ginzberg M, Gagarina V, Zaal KJ, Song Y, et al. Sirtuin 1 enzymatic activity is required for cartilage homeostasis in vivo in a mouse model. Arthritis Rheum. 2013;65(1):159–66.CrossRefPubMedPubMedCentral
29.••
Matsuzaki T, Matsushita T, Takayama K, Matsumoto T, Nishida K, Kuroda R, et al. Disruption of Sirt1 in chondrocytes causes accelerated progression of osteoarthritis under mechanical stress and during ageing in mice. Ann Rheum Dis. 2014;73(7):1397–404. First study to show SIRT1 importance to DMM-induced OA in-vivo transgenic mice.
30.•
Li W, Cai L, Zhang Y, Cui L, Shen G. Intra-articular resveratrol injection prevents osteoarthritis progression in a mouse model by activating SIRT1 and thereby silencing HIF-2α. J Orthop Res. 2015;33(7):1061–70. An in vivo investigation displaying protecting effects of resveratrol on articular cartilage degeneration.CrossRefPubMed
31.
Lim HD, Kim YS, Ko SH, Yoon IJ, Cho SG, Chun YH, et al. Cytoprotective and anti-inflammatory effects of melatonin in hydrogen peroxide-stimulated CHON-001 human chondrocyte cell line and rabbit model of osteoarthritis via the SIRT1 pathway. J Pineal Res. 2012;53(3):225–37.CrossRefPubMed
32.
33.•
Xia X, Guo J, Lu F, Jiang J. SIRT1 plays a protective role in intervertebral disc degeneration in a puncture-induced rodent model. Spine (Phila Pa 1976). 2015;40(9):E515–24. First study to show the protective attributes of SIRT1 in IVD degeneration.CrossRef
34.
Oppenheimer H, Kumar A, Meir H, Schwartz I, Zini A, Haze A, et al. Dvir-Ginzberg M Set7/9 impacts COL2A1 expression through binding and repression of SirT1 histone deacetylation. J Bone Miner Res. 2014;29(2):348–60.CrossRefPubMed
35.
Fujita N, Matsushita T, Ishida K, Kubo S, Matsumoto T, Takayama K, et al. Potential involvement of SIRT1 in the pathogenesis of osteoarthritis through the modulation of chondrocyte gene expressions. J Orthop Res. 2011;29(4):511–5.CrossRefPubMed
36.
Hong EH, Yun HS, Kim J, Um HD, Lee KH, Kang CM, et al. Nicotinamide phosphoribosyltransferase is essential for interleukin-1beta-mediated dedifferentiation of articular chondrocytes via SIRT1 and extracellular signal-regulated kinase (ERK) complex signaling. J Biol Chem. 2011;286(32):28619–31.CrossRefPubMedPubMedCentral
37.
Matsushita T, Sasaki H, Takayama K, Ishida K, Matsumoto T, Kubo S, et al. The overexpression of SIRT1 inhibited osteoarthritic gene expression changes induced by interleukin-1β in human chondrocytes. J Orthop Res. 2013;31(4):531–7.CrossRefPubMed
38.
39.••
Takayama K, Ishida K, Matsushita T, Fujita N, Hayashi S, Sasaki K, et al. SIRT1 regulation of apoptosis of human chondrocytes. Arthritis Rheum. 2009;60(9):2731–40. This paper elegantly shows the survival effect exerted by SIRT1 in chondrocytes, through its effect on mitochondrial proteins.CrossRefPubMed
40.
Gagarina V, Gabay O, Dvir-Ginzberg M, Lee EJ, Brady JK, Quon MJ, et al. SirT1 enhances survival of human osteoarthritic chondrocytes by repressing protein tyrosine phosphatase 1B and activating the insulin-like growth factor receptor pathway. Arthritis Rheum. 2010;62(5):1383–92.CrossRefPubMedPubMedCentral
41.•
Wang D, Hu Z, Hao J, He B, Gan Q, Zhong X, et al. SIRT1 inhibits apoptosis of degenerative human disc nucleuspulposus cells through activation of Akt pathway. Age (Dordr). 2013;35(5):1741–53. This work with nucleus pulposus (NP) cells supports that SIRT1 activates AKT pathway to prevent apoptosis.
42.••
Jiang W, Zhang X, Hao J, Shen J, Fang J, Dong W, et al. SIRT1 protects against apoptosis by promoting autophagy in degenerative human disc nucleus pulposus cells. Sci Rep. 2014;4:7456. This report displays compelling data to support that human disc degeneration is repressed by the pro-survival attributes of SIRT1 via autophagy regulation.CrossRefPubMedPubMedCentral
43.
Miyazaki S, Kakutani K, Yurube T, Maeno K, Takada T, Zhang Z, et al. Recombinant human SIRT1 protects against nutrient deprivation-induced mitochondrial apoptosis through autophagy induction in human intervertebral disc nucleus pulposus cells. Arthritis Res Ther. 2015;17:253.CrossRefPubMedPubMedCentral
44.••
Lei M, Wang J, Xiao D, Fan M, Wang D, Xiong J, et al. Resveratrol inhibits interleukin 1β-mediated inducible nitric oxide synthase expression in articular chondrocytes by activating SIRT1 and thereby suppressing nuclear factor-κB activity. Eur J Pharmacol. 2012;674:73–9. This report shows the inhibitory impact of SIRT1 on RelA during pro-inflammatory stimuli.CrossRefPubMed
45.
Hong EH, Lee SJ, Kim JS, Lee KH, Um HD, Kim JH, et al. Ionizing radiation induces cellular senescence of articular chondrocytes via negative regulation of SIRT1 by p38 kinase. J Biol Chem. 2010;285(2):1283–95.CrossRefPubMed
46.
Brandl A, Hartmann A, Bechmann V, Graf B, Nerlich M, Angele P. Oxidative stress induces senescence in chondrocytes. J Orthop Res. 2011;29(7):1114–20.CrossRefPubMed
47.••
Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458(7241):1056–60. This breakthrough study shows the impact of ATP and AMPK on SIRT1 activity via NAD metabolism, indicating that SIRT1 activity is also susceptible to energy expenditure.
48.••
Wang Y, Zhao X, Lotz M, Terkeltaub R, Liu-Bryan R. Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor γ coactivator 1α. Arthritis Rheumatol. 2015;67(8):2141–53. 48 and 49 are elegant reports highlighting the convergence between AMPK and SIRT1 in regulating chondrocyte energy status in OA pathogenesis.CrossRefPubMedPubMedCentral
49.
50.
Yang S, Ryu JH, Oh H, Jeon J, Kwak JS, Kim JH, et al. NAMPT (visfatin), a direct target of hypoxia-inducible factor-2α, is an essential catabolic regulator of osteoarthritis. Ann Rheum Dis. 2015;74(3):595–602.CrossRefPubMed
51.
Oh H, Kwak JS, Yang S, Gong MK, Kim JH, Rhee J, et al. Reciprocal regulation by hypoxia-inducible factor-2α and the NAMPT-NAD(+)-SIRT axis in articular chondrocytes is involved in osteoarthritis. Osteoarthritis Cartilage. 2015;23(12):2288–96.CrossRefPubMed
52.•
Yammani RR, Loeser RF. Extracellular nicotinamidephosphoribosyltransferase (NAMPT/visfatin) inhibits insulin-like growth factor-1 signaling and proteoglycan synthesis in human articular chondrocytes. Arthritis Res Ther. 2012;14(1):R23. First study to examine the endocrine effect of eNAMPT/visfatin in OA.CrossRefPubMedPubMedCentral
53.
Laiguillon MC, Houard X, Bougault C, Gosset M, Nourissat G, Sautet A, et al. Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis. Arthritis Res Ther. 2014;16(1):R38.CrossRefPubMedPubMedCentral
54.
Pecchi E. Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain. Arthritis Res Ther. 2014;16(1):R16.CrossRefPubMedPubMedCentral
55.
Présumey J, Courties G, Louis-Plence P, Escriou V, Scherman D, Pers YM, et al. Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis. Ann Rheum Dis. 2013;72(10):1717–24.CrossRefPubMed
56.•
Dvir-Ginzberg M, Gagarina V, Lee EJ, Booth R, Gabay O, Hall DJ. Tumor necrosis factor α-mediated cleavage and inactivation of SirT1 in human osteoarthritic chondrocytes. Arthritis Rheum. 2011;63(8):2363–73. This report highlights that pro-inflammatory stimuli, causes SIRT1 truncation and inactivation in OA chondrocytes.CrossRefPubMedPubMedCentral
57.
Gardner PJ, Yazid S, Chu CJ, Copland DA, Adamson P, Dick AD, et al. TNFα regulates SIRT1 cleavage during ocular autoimmune disease. Am J Pathol. 2015;185(5):1324–33.CrossRefPubMed
58.
Chen J, Xavier S, Moskowitz-Kassai E, Chen R, Lu CY, Sanduski K, et al. Cathepsin cleavage of sirtuin 1 in endothelial progenitor cells mediates stress-induced premature senescence. Am J Pathol. 2012;180(3):973–83.CrossRefPubMedPubMedCentral
59.
Ben-Aderet L, Merquiol E, Fahham D, Kumar A, Reich E, Ben-Nun Y, et al. Detecting cathepsin activity in human osteoarthritis via activity-based probes. Arthritis Res Ther. 2015;17:69.CrossRefPubMedPubMedCentral
60.•
Niederer F, Ospelt C, Brentano F, Hottiger MO, Gay RE, Gay S, et al. SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance. Ann Rheum Dis. 2011;70(10):1866–73. This is the first report showing how SIRT1 impact synovitis in rheumatoid arthritis.CrossRefPubMed
61.
Kok SH, Lin LD, Hou KL, Hong CY, Chang CC, Hsiao M, et al. Simvastatin inhibits cysteine-rich protein 61 expression in rheumatoid arthritis synovial fibroblasts through the regulation of sirtuin-1/FoxO3a signaling. Arthritis Rheum. 2013;65(3):639–49.CrossRefPubMed
62.••
Burnett C, Valentini S, Cabreiro F, Goss M, Somogyvári M, Piper MD, et al. Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature. 2011;477(7365):482–5. This study shows that the effect of lifespan extension exerted by Sir2 may be influenced by adverse genetic background and thereby may not robustly present a significant extension in lifespan.
63.••
Wu Y, Chen L, Wang Y, Li W, Lin Y, Yu D, et al. Overexpression of Sirtuin 6 suppresses cellular senescence and NF-Κb mediated inflammatory responses in osteoarthritis development. Sci Rep. 2015;5:17602. An important report showing that Sirt6 is a key regulator in OA pathogenesis.CrossRefPubMedPubMedCentral
64.•
Nagai K, Matsushita T, Matsuzaki T, Takayama K, Matsumoto T, Kuroda R, et al. Depletion of SIRT6 causes cellular senescence, DNA damage, and telomere dysfunction in human chondrocytes. Osteoarthritis Cartilage. 2015;23(8):1412–20. An important report showing that Sirt6 protects from DNA damage in OA pathogenesis.CrossRefPubMed
65.••
Piao J, Tsuji K, Ochi H, Iwata M, Koga D, Okawa A, et al. Sirt6 regulates postnatal growth plate differentiation and proliferation via Ihh signaling. Sci Rep. 2013;3:3022. An important report showing that Sirt6 regulates Ihh activity in cartilage growth plate.CrossRefPubMed
66.
Lin J, Sun B, Jiang C, Hong H, Zheng Y. Sirt2 suppresses inflammatory responses in collagen-induced arthritis. Biochem Biophys Res Commun. 2013;441(4):897–903.CrossRefPubMed
67.•
Lee HS, Ka SO, Lee SM, Lee SI, Park JW, Park BH. Overexpression of sirtuin 6 suppresses inflammatory responses and bone destruction in mice with collagen-induced arthritis. Arthritis Rheum. 2013;65(7):1776–85. In this report, Sirt6 is shown to reduce inflammation in a murine RA model.CrossRefPubMed
68.
Engler A, Niederer F, Klein K, Gay RE, Kyburz D, Camici GG, et al. SIRT6 regulates the cigarette smoke-induced signaling in rheumatoid arthritis synovial fibroblasts. J Mol Med (Berl). 2014;92(7):757–67.CrossRef
69.••
Fu Y, Kinter M, Hudson J, Humphries KM, Lane RS, White JR, et al. Aging promotes SIRT3-dependent cartilage SOD2 acetylation and osteoarthritis. Arthritis Rheumatol. 2016. doi:10.​1002/​art.​39618. [Epub ahead of print]. First paper to show that Sirt3 plays an essential role in OA via regulating mitochondrial activity.
70.
Dieppe PA, Cushaghan D, Jasani MK, et al. A two year placebo controlled trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint. Br J Rheumatol. 1993;32:595–600.CrossRefPubMed
71.
Williams HJ, Ward JR, Egger MJ, et al. Comparison of naproxen and acetaminophen in a two year study of treatment of osteoarthritis of the knee. Arthritis Rheum. 1993;36:1196–206.CrossRefPubMed
72.
Mobasheri A. Osteoarthritis year 2012 in review: biomarkers. Osteoarthritis Cartilage. 2012;20(12):1451–64.CrossRefPubMed
73.
Rousseau JC, Delmas PD. Nat Clin Pract Rheumatol. 2007;3(6):346–56. Biological markers in osteoarthritis.
74.
Jotanovic Z, Mihelic R, Sestan B, Dembic Z. Emerging pathways and promising agents with possible disease modifying effect in osteoarthritis treatment. Curr Drug Targets. 2014;15:635–661.
75.•
Buhrmann C, Busch F, Shayan P, Shakibaei M. Sirtuin-1 (SIRT1) is required for promoting chondrogenic differentiation of mesenchymal stem cells. J Biol Chem. 2014;289(32):22048–62. Important paper presenting data to show that SIRT1 is essential for chondrogenesis of mesenchymal progenitors.CrossRefPubMedPubMedCentral
76.
Edwards JR, Perrien DS, Fleming N, Nyman JS, Ono K, Connelly L, et al. Silent information regulator (Sir)T1 inhibits NF-κB signaling to maintain normal skeletal remodeling. J Bone Miner Res. 2013;28(4):960–9.CrossRefPubMed
77.
Cohen-Kfir E, Artsi H, Levin A, Abramowitz E, Bajayo A, Gurt I, et al. Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology. 2011;152(12):4514–24.CrossRefPubMed
Metadata
Title
The Role of Sirtuins in Cartilage Homeostasis and Osteoarthritis
Authors
Mona Dvir-Ginzberg
Ali Mobasheri
Ashok Kumar
Publication date
01-07-2016
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 7/2016
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-016-0591-y

Other articles of this Issue 7/2016

Current Rheumatology Reports 7/2016 Go to the issue

Erratum

Erratum to: The Role of Sirtuins in Cartilage Homeostasis and Osteoarthritis

Systemic Lupus Erythematosus (A Saxena, Guest Section Editor)

Update on Biologic Therapies for Systemic Lupus Erythematosus

Surgery and Perioperative Care (CR MacKenzie and SM Goodman, Section Editors)

Stress Dose Steroids: Myths and Perioperative Medicine

Health Economics and Quality of Life (M Harrison, Section Editor)

Incentives in Rheumatology: the Potential Contribution of Physician Responses to Financial Incentives, Public Reporting, and Treatment Guidelines to Health Care Sustainability

Osteoarthritis (MB Goldring, Section Editor)

Non-invasive Loading Model of Murine Osteoarthritis

Pediatric Rheumatology (S Ozen, Section Editor)

Biologics in Pediatric Rheumatology: Quo Vadis?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits